# Canary Capital Amends Proposed Staked Injective ETF Filing With SEC

By Riza Dagoc

Canonical URL: https://www.tokenpost.com/news/regulation/24195
Published: 2026-09-25T15:10:08.000Z
Updated: 2026-09-25T15:10:08.000Z
Section: Regulation

> The proposed fund would hold Injective (INJ), stake most assets and seek listing under the INJS ticker on Cboe BZX, subject to approval.

Canary Capital amended its proposed staked Injective ETF filing June 25, outlining a fund that would give U.S. investors exposure to Injective (INJ) while seeking additional INJ through network staking, subject to regulatory and exchange approval.

The proposed Canary Staked INJ ETF would seek to reflect the value of INJ held by the trust, with staking rewards listed as a secondary investment objective. Shares are expected to trade under the INJS ticker on Cboe BZX if the fund receives the required approvals.

The filing identifies the CoinDesk Injective USD CCIXber 60m New York Rate as the fund’s pricing benchmark. Shares would be created and redeemed in baskets of 10,000 shares.

The sponsor generally intends to stake the trust’s INJ, except for assets held for redemptions, expenses or protection of the trust. Staking rewards would be subject to fees, and the trust would retain only part of the rewards generated by its staking provider.

BitGo Trust Company Inc. is listed as custodian for the trust’s INJ. U.S. Bank, N.A. would serve as cash custodian, while U.S. Bancorp Fund Services, LLC would act as transfer agent.

The registration statement does not authorize the ETF to launch or begin trading. A separate SEC review is required for Cboe BZX’s proposed rule change to list the shares.

The exchange’s earlier application was withdrawn March 9, 2026, after the SEC instituted proceedings on the proposal in November 2025.

The amended filing follows Canary Capital’s original proposal for a U.S. ETF offering exposure to staked INJ, filed July 17, 2025.